Health technology assessment in Poland, the Czech Republic, Hungary, Romania and Bulgaria

European Journal of Health Economics

Volumn 15, Issue SUPPL. 1, 2014, Pages

  Gulácsi, László ^a   Rotar, Alexandru M ^b   Niewada, Maciej ^c,d   Löblová, Olga ^e   Rencz, Fanni ^a   Petrova, Guenka ^f   Boncz, Imre ^g   Klazinga, Niek S ^a  

^a Institute of Entrepreneurship and Innovation   (Hungary)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c MEDICAL UNIVERSITY OF WARSAW   (Poland)

^d HealthQuest Consulting Company   (Poland)

^e CENTRAL EUROPEAN UNIVERSITY   (Hungary)

^f MEDICAL UNIVERSITY OF SOFIA   (Bulgaria)

^g UNIVERSITY OF PÉCS   (Hungary)

Author keywords

Bulgaria; Czech Republic; Health technology assessment; Hungary; Poland; Romania

Indexed keywords

ACCREDITATION; ARTICLE; BULGARIA; CLINICAL ASSESSMENT TOOL; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; CZECH REPUBLIC; DECISION MAKING; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH CARE SYSTEM; HEALTH ECONOMICS; HEALTH TECHNOLOGY ASSESSMENT; HUMAN; HUNGARY; INSTITUTIONALIZATION; MEDICAL TECHNOLOGY; METHODOLOGY; POLAND; PRIORITY JOURNAL; REIMBURSEMENT; ROMANIA; STANDARD; STANDARDIZATION; BIOMEDICAL TECHNOLOGY ASSESSMENT; COMPARATIVE STUDY; EASTERN EUROPE; LEGISLATION AND JURISPRUDENCE; MANAGEMENT; ORGANIZATION; STANDARDS; STATISTICS AND NUMERICAL DATA; UTILIZATION;

DECISION MAKING, ORGANIZATIONAL; EUROPE, EASTERN; HEALTH EXPENDITURES; HUMANS; POLICY MAKING; REIMBURSEMENT MECHANISMS; TECHNOLOGY ASSESSMENT, BIOMEDICAL;

EID: 84905706696     PISSN: 16187598     EISSN: 16187601     Source Type: Journal    
DOI: 10.1007/s10198-014-0590-8     Document Type: Article

References (41)

1. Order No 1/2010 of President of AHTAPol dated 4 January 2010 on guidelines on health technology assessment. English-http://www.aotm.gov.pl/ assets/files/wytyczne-hta/2009/Guidelines-HTA-eng-MS-29062009.pdf (02-02-2014)
2. Regulation of the Minister of Health of 2 April 2012 on the minimum requirements to be satisfied by analyses accounted for in the applications for reimbursement and setting the official sales price and for increasing the official sales price of a drug, a special purpose dietary supplement, a medical device, which do not have a reimbursed counterpart in a given indication. http://www.aotm.gov.pl/assets/files/wytyczne-hta/2012/Regulation-MoH-minimum- requirements-03042012-eng.pdf (02-02-2014)
3. Act on the Reimbursement of Drugs, Food Products for Special Dietary Purposes and Medical Devices with Public Funds 12 May 2011, Journal of Laws 2011 No 122, Poz. 696
4. Kolasa, K., Schubert, S., Manca, A., Hermanowski, T.: A review of health technology assessment (HTA) recommendations for drug therapies issued between 2007 and 2009 and their impact on policymaking processes in Poland. Health Policy 102, 145-151 (2011)
5. Kolasa, K., Wasiak, R.: Health technology assessment in Poland and Scotland: comparison of process and decisions. Int. J. Tech. Assess. Health Care 27(1), 70-76 (2011)
6. Niewada, M., Polkowska, M., Jakubczyk, M., Golicki, D.: What influences recommendations issued by the agency for health technology assessment in Poland? A glimpse into decision makers' preferences, Value in Health Regional Issues 2, 267-272 (2013)
7. CTK. Heger dal vládě 14 opatření ke zlepšení financí ve zdravotnictví. MEDICAL TRIBUNE CZ. http://www.tribune.cz/clanek/28311-heger-dal-vlade-opatreni-ke-zlepseni- financi-ve-zdravotnictvi (2012)
8. Vepřek, P.: Reforma zdravotnictví a role HTA České zdravotnictví. PowerPoint presentation (2012)
9. Vepřek, P. HTA v České republice (2013)
10. Státní úřad pro kontrolu léčiv. SP-CAU-027-W Postup pro hodnocení dopadu do rozpočtu. http://www.sukl.cz/file/73503-1-1 (2012)
11. Státní úřad pro kontrolu léčiv. 01-A-SP-CAU-028 Postup pro hodnocení ná kladové efektivity. http://www.sukl.cz/file/73935 (2013)
12. Ministerstvo zdravotnictví ČR. Ministr Němeč ek odvolal šéfa Státního ústavu pro kontrolu léčiv. Press Release. http://www.mzcr.cz/dokumenty/ministr- nemecek-odvolal-sefa-statniho-ustavu-pro-kontrolu-leciv--8725-1.html (2014)
13. Böhm, K., Landwehr, C.: The Europeanization of health care coverage decisions: EU-regulation, policy learning and cooperation in decision-making. J. Eur. Integr. 36(1), 17-35 (2014). doi:10.1080/07036337.2013.793679
14. Dolezal, T.: Hranice ochoty platitt ve světěv podmínkǎ ch ČR. In Diskusní setkání z cyklu "Dialogem k reformě "sdružení Občan: "Hranice ochoty platit - proč, jak, kdy?" Prague, 22 May 2013 (2013)
15. Vrubel, F.: Stanovisko k úhradám vysoce inovativních přípravků., Pub. L. No. MZDR10517/2012. http://www.mzcr.cz/Odbornik/dokumenty/stanovisko-k-uhradam-vysoce-inova tivnich-lecivych-pripravku-6116-1954-3.html (2012)
16. Prochazkova, M., Kubickova, P., Mazelova, J., Hambalek, J., Heislerova, M.: PHP130 - pricing and reimbursement system of orphan drugs in the Czech Republic. Value Health 16(7), A474 (2013). doi:10.1016/j.jval.2013.08.880
17. Allen, N., Pichler, F., Wang, T., Patel, S., Salek, S.: Development of archetypes for non-ranking classification and comparison of European National Health Technology Assessment systems. Health Policy 113(3), 305-312 (2013). doi:10.1016/j.healthpol.2013.09.007
18. MoH 2013 Az Emberi Eriforrások Minisztériuma szakmai irányelve, az egészség-gazdaságtani elemzések készítéséhez, 2013. EüK. 3. szám EMMI közlemény 2 (hatályos: 2013.03.01)
19. Jóna G.: A GYEMSZI Technológia- értékelo{combining double acute accent} Fo{combining double acute accent}osztály tapasztalataiból. Corvinus Health Policy Series Conference 2011.10.03. Budapest
20. Jóna, G., Kozma, P.O., Nádudvari, N., Kárpá ti, K.: Gyógyszerkibocsátó stentek alkalmazása percutan coronaria intervencióban A szakirodalom szisztematikus áttekintése, ESKI 2006 Budapest
21. 28/2010. (12/05/2010) Decree of the Ministry of Health in Hungary
22. Endrei, D., Molics, B., Ágoston, I.: Multicriteria decision analysis in the reimbursement of new medical technologies: real word experiences from Hungary, Value in Health. doi:10.1016/j.jval.2014.01.011
23. http://www.imf.org/external/np/loi/2011/rou/091411.pdf
24. Lopert, R., Ruiz, F., Chalkidou, K.: Applying rapid 'de-facto' HTA in resource-limited settings: experience from Romania. Health Policy 112, 202-208 (2013)
25. Ruiz, F., Lopert, R., Chalkidou, K.: Technical assistance in reviewing the content and listing processes for the Romanian basic package of health services and technologies, NICE International, January 2012. http://www.medalert.ro/sites/default/files/attachments/ Evaluarea%20listei%20de%20medicamente%20compensate-raport%20NICE%202012.pdf
26. http://www.ms.gov.ro/?pag=19&id=9415
27. MoH http://www.ms.ro/documente/ORDIN%20HTA-772-1523.pdf and MoH 2013 August http://www.ms.gov.ro/?pag=178&id=12749 (2013)
28. http://www.has-sante.fr/portail/jcms/r-1506267/fr/le-service-medical- rendu-smr-et-lamelioration-du-service-medical-rendu-asmr
29. https://www.evidem.org/components-decision.php
30. http://www.ms.gov.ro/?pag=178&id=12749
31. http://www.ms.gov.ro/?pag=178&id=12965
32. http://www.ms.gov.ro/?pag=178&id=13053
33. Law for medicines in human medicine. Governmental Gazette N 31, April 13 2007; last amended Gov. gazette 1, January 3, 2014
34. National Health Insurance Act. Governmental Gazette 70, June 19, 1998, last amended Gov. Gazette 1, January 3, 2014
35. Ministry Council Decree 97/19.04.2013, Governmental Gazette 40/30.04.2013
36. NICE: Developing NICE multiple technology appraisals (MTAs), http://www.nice.org.uk/aboutnice/howwework/devnicetech/developing-nice-multiple- technology-appraisals.jsp, Retrieved on 7/3/2014 (2013)
37. Downing, N.S., Aminawung, J.A., Shah, N.D., Krumholz, H.M., Ross, J.S.: Clinical trial evidence supporting FDA approval of novel therapeutic agents, 2005-2012. JAMA 311 (4), 368-377 (2014). doi:10.1001/jama.2013.282034
38. Cleemput, I., Neyt, M., Thiry, N., Laet, C., Leys, M.: Using threshold values for cost per quality-adjusted life year gained in health care decisions. Int. J. Technol. Assess. Health Care 27, 71-76 (2011)
39. McCabe, C., Claxton, K., Culyer, A.J.: The NICE cost-effectiveness threshold. What it is and what that means. Pharmacoeconomics 26(9), 733-744 (2008)
40. Gulácsi, L., Péntek, M., Brodszky, V.: Az egészségügyi technológiák finanszí rozása; tudjuk-e mit veszünk a milliárdokért? Esély 2, 3-27 (2011)
41. Gulácsi, L., Boncz, I., Drummond, M.: Issues for countries considering introducing the 'fourth hurdle'; the case of Hungary. Int. J. Technol. Assess. Health Care 20(3), 337-341 (2004)